Evidence map›Paper›PMID 36913086›Full record

ReviewAnnals of biomedical engineering2024

Challenges and Perspectives for Future Considerations in the Bioengineering of a Bioartificial Pancreas.

Amoge Opara, Priyadarshini Canning, Abdelrahman Alwan, Emmanuel C Opara

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amoge OparaDiabetes Section, Biologics Delivery Technologies, Reno, NV, 89502, USA.
Priyadarshini CanningWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Abdelrahman AlwanWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Emmanuel C OparaDiabetes Section, Biologics Delivery Technologies, Reno, NV, 89502, USA. eopara@wakehealth.edu.ORCID http://orcid.org/0000-0002-3486-1453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an unrelenting interest in the development of a reliable bioartificial pancreas construct since the first description of this technology of encapsulated islets by Lim and Sun in 1980 because it promised to be a curative treatment for Type 1 Diabetes Mellitus (T1DM). Despite the promise of the concept of encapsulated islets, there are still some challenges that impede the full realization of the clinical potential of the technology. In this review, we will first present the justification for continued research and development of this technology. Next, we will review key barriers that impede progress in this field and discuss strategies that can be used to design a reliable construct capable of effective long-term performance after transplantation in diabetic patients. Finally, we will share our perspectives on areas of additional work for future research and development of the technology.

Indexed as

Diabetes Mellitus, Type 1Pancreas, ArtificialAnimalsBioengineeringHumansIslets of Langerhans TransplantationTissue EngineeringDiabetesInsulin deliveryIslets encapsulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.